Skip to main content

Looking for Valuant? You are in the right place!

Valuant is now Abrigo, giving you a single source to Manage Risk and Drive Growth

Make yourself at home – we hope you enjoy your new web experience.

Looking for DiCOM? You are in the right place!

DiCOM Software is now part of Abrigo, giving you a single source to Manage Risk and Drive Growth. Make yourself at home – we hope you enjoy your new web experience.

Looking for TPG Software? You are in the right place!

TPG Software is now part of Abrigo. You can continue to count on the world-class Investment Accounting software and services you’ve come to expect, plus all that Abrigo has to offer.

Make yourself at home – we hope you enjoy being part of our community.

Marijuana reclassification: What it means for financial institutions and cannabis banking in 2026

Terri Luttrell, CAMS-Audit, CFCS
December 29, 2025
0 min read

Marijuana reclassification: What it means for financial institutions and cannabis banking 

The cannabis industry received a long-awaited policy shift in December when President Donald Trump signed an executive order instructing the Department of Justice (DOJ) to reclassify marijuana from a Schedule I to a Schedule III substance under the Controlled Substances Act (CSA). The move is historic, marking the most significant change to federal drug policy in over 50 years. While this decision does not equate to full legalization, it signals a major pivot with broad implications for cannabis banking, compliance teams, and financial institutions.

The order directs the DOJ to initiate the formal rulemaking process to reclassify marijuana; however, the timeline for completing this process remains uncertain. The order mandates the expediting of rescheduling, so the change is anticipated soon.

Learn more about Nacha's 2026 fraud monitoring rules

Read the whitepaper

What reclassification means, and what it doesn’t

Reclassifying marijuana from Schedule I to Schedule III recognizes its potential medical use and a lower risk for abuse compared to drugs like heroin or LSD. The order, once finalized by the Drug Enforcement Administration, moves cannabis out of the most restrictive category under the CSA to a Schedule III classification, which encompasses substances with accepted medical use, such as ketamine and Tylenol with codeine.

With this change, cannabis businesses will no longer be subject to the restrictive tax code, which currently bars them from deducting standard business expenses. As a result, the industry stands to unlock billions in capital, with more favorable tax treatment and renewed investor confidence.

Rescheduling marijuana is not a green light for nationwide legalization. Marijuana remains federally illegal for recreational use, and the state-by-state regulatory patchwork remains intact. For financial institutions, this means that uncertainty remains, particularly for compliance and anti-money laundering (AML) teams.

 

Legislation targets “intoxicating” hemp loopholes

Adding to the complexity is a growing legislative trend aimed at regulating intoxicating hemp-derived products such as delta-8 or delta-9 THC. While the 2018 Farm Bill legalized hemp containing less than 0.3% THC, the loophole left room for the sale of psychoactive hemp products that are not yet regulated like marijuana. On November 12, 2025, Congress passed legislation to reimpose federal controls over certain hemp products, closing the Farm Bill loophole.

For financial institutions, this creates a gray area. Businesses selling delta-8, delta-9, or similar products may fall outside current cannabis laws but still pose elevated compliance risks. Cannabis banking programs should reassess their customer due diligence processes to determine how the sale of hemp-derived products is evaluated and monitored.

Institutions weigh opportunities with caution

In a recent Abrigo survey of financial institution professionals, respondents showed cautious optimism about entering or expanding cannabis banking services. When asked whether the reclassification made them more or less likely to bank cannabis-related businesses, 22% said they were less likely, and 11% reported being more likely. Meanwhile, 45% of respondents reported being unsure, underscoring the ongoing uncertainty surrounding federal and state regulatory frameworks. These findings highlight the importance of developing risk-based strategies and engaging in informed discussions at the board and executive levels before making a decision.

Get a free AI readiness checklist and other resources on Abrigo's AI Hub.

AI resources for bankers

 

Navigating risk

Financial institutions already engaged in cannabis banking, or those considering entering this space, must continue to treat cannabis-related businesses (CRBs) as high-risk clients. While reclassification may ease some public perception challenges, federal law has not yet changed enough to remove cannabis from heightened regulatory scrutiny. As with any cash-intensive business, CRBs require additional monitoring.

Institutions need to:

  • Conduct enhanced due diligence and ongoing monitoring of CRB accounts
  • Stay informed on updates to FinCEN guidance related to CRBs
  • Document decisions carefully and ensure board-level oversight for cannabis banking programs

For those new to cannabis banking, this policy shift presents a strategic opportunity to assess risk appetite and explore potential revenue streams. It also highlights the need for comprehensive AML staffing assessments to ensure teams are equipped to handle these complex customer relationships.

Assess AML staffing needs

As the cannabis banking landscape evolves, institutions must ensure that staffing levels align with new workloads and regulatory expectations. Even with the easing of classification, CRBs still carry operational and reputational risks. A robust AML program, backed by appropriate staffing, remains non-negotiable.

Staffing assessments can help financial institutions:

  • Identify gaps in transaction monitoring coverage
  • Allocate resources effectively for high-risk accounts
  • Support business decisions with data-driven insights

Whether assessments are performed internally or by a third-party provider, demonstrating a commitment to strong internal controls is crucial as federal agencies continue to refine their stance on cannabis.

The cannabis banking opportunity

With the U.S. cannabis market expected to exceed $32 billion, reclassification may catalyze a new wave of legitimate financial services offerings. For community banks and credit unions, it presents a rare opportunity to serve a growing industry often locked out of the traditional banking system.

To prepare, financial institutions should:

  • Revisit their risk assessments and cannabis banking policies
  • Engage with regulators and peer institutions to understand best practices
  • Educate staff across compliance, lending, and operations functions

These steps ensure readiness not just for current compliance requirements, but for future shifts that may follow reclassification, including potential changes to AML/CFT guidelines.

A cautious but strategic approach

The reclassification of marijuana to Schedule III represents progress, but not clarity. Cannabis banking remains a complex and highly regulated endeavor. Financial institutions must remain cautious, deliberate, and informed as they weigh the risks and opportunities in this space. While previous attempts to establish a federal safe harbor for cannabis banking, such as the SAFER Banking Act, have repeatedly stalled in the U.S. Senate, the rescheduling of marijuana could improve the political environment for future legislative progress.

By conducting staffing assessments, updating policies, and maintaining strong oversight, financial institutions can position themselves to serve cannabis-related businesses responsibly and effectively. Now more than ever, compliance professionals have a crucial role in shaping the future of cannabis banking.

 

About the Author

Terri Luttrell, CAMS-Audit, CFCS

Compliance and Engagement Director
Terri Luttrell is a seasoned AML professional and former director and AML/OFAC officer with over 20 years in the banking industry, working both in medium and large community and commercial banks ranging from $2 billion to $330 billion in asset size.

Full Bio

About Abrigo

Abrigo enables U.S. financial institutions to support their communities through technology that fights financial crime, grows loans and deposits, and optimizes risk. Abrigo's platform centralizes the institution's data, creates a digital user experience, ensures compliance, and delivers efficiency for scale and profitable growth.

Make Big Things Happen.